Lifestyle Intervention Reduces Risk Score for Cardiovascular Mortality in Company Employees with Pre-diabetes or Diabetes Mellitus - A Secondary Analysis of the PreFord Randomized Controlled Trial with 3 Years of Follow-up
Overview
Authors
Affiliations
Aim: To evaluate the effects of a multimodal intervention (including exercise training, psychosocial interventions, nutrition coaching, smoking cessation program, medical care) on the health and long-term cardiovascular disease (CVD) mortality risk of company employees with pre-diabetes or diabetes mellitus (DM) at high CVD risk.
Methods: In the PreFord study, German company employees (n=4196) participated in a free-of-charge CVD mortality risk screening at their workplace. Based on their European Society of Cardiology - Systematic Coronary Risk Evaluation score (ESC-SCORE), they were subdivided into three risk groups. High-risk patients (ESC-SCORE≥5%) were randomly assigned to a 15-week lifestyle intervention or usual care control group. Data from patients with pre-DM/DM were analyzed intention-to-treat (ITT: n=110 versus n=96) and per protocol (PP: n=60 versus n=52).
Results: Body mass index, glycated hemoglobin, total cholesterol, low-density lipoprotein, triglyceride levels as well as systolic and diastolic blood pressure improved through the intervention (ITT, PP: p<0.001). The ESC-SCORE markedly decreased from pre- to post-intervention (ITT, PP: p<0.001). ESC-SCORE changes from baseline differed significantly between the groups, with the intervention group achieving more favorable results in all follow-up visits 6, 12, 24 and 36 months later (at each time point: ITT: p<0.001; PP: p ≤ 0.010).
Conclusion: The study demonstrates the feasibility of attracting employees with pre-DM/DM at high CVD mortality risk to participate in a multimodal lifestyle program following a free CVD mortality risk screening at their workplace. The lifestyle intervention used in the PreFord study shows high potential for improving health of company employees with pre-DM/DM in the long term. ISRCTN23536103.
Fan S, Yang Y, Li X, Liu J, Qiu Y, Yan L Front Endocrinol (Lausanne). 2024; 15:1380163.
PMID: 38846488 PMC: 11153693. DOI: 10.3389/fendo.2024.1380163.
Xi H, Jing M, Sun Q, Wang Y, Zhu H, Zhou J Heliyon. 2024; 10(3):e25316.
PMID: 38352755 PMC: 10861983. DOI: 10.1016/j.heliyon.2024.e25316.
Lean nonalcoholic fatty liver disease and sarcopenia.
Chen M, Cao Y, Ji G, Zhang L Front Endocrinol (Lausanne). 2023; 14:1217249.
PMID: 37424859 PMC: 10327437. DOI: 10.3389/fendo.2023.1217249.